Powered by
ANN ARBOR—HistoSonics Inc. announced that it had received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new technology, …
CANTON TWP.—MMS Holdings Inc. said that its collaboration with Shanghai-based Green Valley Pharmaceutical Co. resulted in gaining U.S. Food & Drug Administration approval of an Investigational New Drug application for …
DETROIT—An oral therapy that has been studied in laboratory experiments and clinical trials at the Barbara Ann Karmanos Cancer Institute, in partnership with Karyopharm Therapeutics Inc., will soon enter clinical …
CANTON TWP.—MMS Holdings Inc., a contract research organization for the pharmaceutical industry, announced the hiring of Kelly Valliant as director of global transparency strategy and compliance. Vaillant will lead transparency …
CANTON TWP.—TrialAssure, a software company focused on developing clinical trial transparency tools, announced that it will offer academic institutions free access to TrialAssure Registry, its clinical trial disclosure reporting application. …
ANN ARBOR—Millendo Therapeutics Inc., a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases, announced today that it is discontinuing the development of livoletide as a potential treatment …
ALLENDALE—QST Consultations Ltd. has announced that it has changed its name to Abond CRO Inc., launching the new brand through a new website and participation at participation at the Summit …
FARMINGTON HILLS—Ocuphire Pharma Inc., a startup pharmaceutical company focused on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders, announced statistically significant and clinically …
CANTON TWP.—TrialAssure, developers of clinical trial management software, announced a limited release of a new product, Anonymize R, a document anonymization software that uses machine learning, natural language processing, and …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), the Ann Arbor-based pharmaceutical startup developing a new class of cholesterol-fighting drugs, announced that its lead drug candidate, bempedoic acid, was included in the …